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Abstract 
From patients’ and physicians’ perspectives, the clinical definition of a tumor’s malignant 
phenotype could be restricted to the early diagnosis of sub-types of malignancies with the 
increased risk of existing therapy failure and high likelihood of death from cancer. It is the 
viewpoint from which the understanding of malignant regulatory signatures is considered in this 
contribution. Analyses from this perspective of experimental and clinical observations revealed 
the pivotal role of human stem cell-associated retroviral sequences (SCARS) in the origin and 
pathophysiology of clinically-lethal malignancies. SCARS represent evolutionary- and 
biologically-related family of genomic regulatory sequences, the principal physiological function 
of which is to create and maintain the stemness phenotype during human preimplantation 
embryogenesis. SCARS expression must be silenced during cellular differentiation and SCARS 
activity remains silent in most terminally-differentiated human cells performing specialized 
functions in the human body. De-repression and sustained activation of SCARS result in 
differentiation-defective phenotypes, tissue- and organ-specific clinical manifestations of which 
are diagnosed as pathological conditions defined by a consensus of pathomorphological, 
molecular, and genetic examinations as the malignant growth. Contemporary evidence are 
presented that high-fidelity molecular signals of continuing activities of SCARS in association 
with genomic regulatory networks of thousands’ functionally-active enhancers triggering 
engagements of down-stream genetic loci may serve as both reliable diagnostic tools and 
druggable molecular targets readily amenable for diagnosis and efficient therapeutic 
management of clinically-lethal malignancies.  
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Preface 
The idea that malignant growth originates from stem cells is more than a quarter century old [1]. 
It was revived at the beginning of 21st century as the cancer stem cell theory [2; 3], which 
became one of dominant concepts of the contemporary cancer research. One of the key 
principles of the cancer stem cell theory is that a single cancer stem cell is sufficient to regrow a 
malignant tumor fully recapitulating morphological, molecular, genomic, and biological features 
of the parental tumor. Consequently, the theory predicts that cancer cannot be eradicated 
unless cancer stem cell-targeting therapies [4] will eliminate all cancer stem cells. This postulate 
is believe to be true because if even a single cancer stem cell would escape the therapeutic 
assault, it will continue to fuel the malignant growth. However, some fundamental clinical 
realities seem not necessarily fully compatible with the uniformly simplistic view of the human 
cancer origin and pathogenesis. First, tumors arising in the same organ are not equivalent in 
clinical responses to therapies, which could be correlated to their genetic and molecular 
features. Second, the clinical prognosis related to the organ of cancer origin is markedly 
different for cancers diagnosed in different organs even at the early stages. Third, in many 
instances, the clinical cure of malignant tumors has been achieved by the first-line cancer 
therapies, which are not specifically designed to target cancer stem cells.  
On a parallel track, technological advances enabled genome-wide gene expression profiling 
analyses of human malignancies making a reality the search for gene expression signatures of 
clinically-lethal malignancies, thus, looking for statistically-significant gene expression correlates 
of increased likelihood of existing therapy failure and death from cancer. Historically, the theory 
defining a genomic link between degrees to which a malignancy recapitulates gene expression 
profiles of stem cells and clinical phenotypes of increased likelihood of therapy failure and death 
from cancer is originated from the discovery of the death-from-cancer gene expression 
signature [5]. This genomic connectivity between the phenotypes of resemblance to stemness 
 4 
 
and high likelihood of death from cancer was initially documented for cancer patients diagnosed 
with 12 distinct types of human malignancies [5]. Observations reported in the original 
contributions [5; 6] and follow-up studies (reviewed in 7) directly implicated sustained activation 
of the Polycomb Group (PcG) Proteins chromatin silencing pathway [8], specifically, the BMI1 
genes, as the principal genomic contributor defining these associations [5; 7]. Collectively, these 
observations formed the foundation for a concept stating that malignant clinical behaviors of 
human cancers are governed by stemness genomic laws [5-7; 9-12]. The universal nature of the 
genomic connectivity between the degree of resemblance to stemness and the extent of 
malignant behavior of a tumor was validated in numerous experimental cancer models, 
including transgenic mouse models facilitating implementation of the mouse/human translational 
genomics approach [5; 13; 14]; clinically-relevant orthotopic xenograft models of human cancers 
and xenograft-derived cancer cell lines, including blood-borne metastasis precursor cells [6; 15-
19]. Mechanistic roles of genes essential for functional integrity of PcG chromatin silencing 
pathway were demonstrated using targeted genetic interference approaches [13; 20] and gene-
specific small molecule therapeutics [21]. Overall, multiple studies have shown that BMI1 
inhibition confer therapeutic effects on glioblastoma multioforme, colorectal and breast cancers, 
as well as chemoresistant ovarian, prostate, pancreatic, and skin cancers [21-24].   
However, the major limitation of these and many other early studies was the lack of sufficient 
understanding of the genomic and molecular underpinning of the stemness phenotype as it 
emerges during human preimplantation embryogenesis. Remarkable advances in single cell 
expression profiling analyses of human preimplantation embryos closed this knowledge gap and 
provided the opportunity to address this limitation. Collectively, these advances facilitated the 
discovery of stem cell-associated retroviral sequences, which act as the master genomic 
regulatory elements driving the creation of stemness phenotype in human embryos and may be 
responsible for its emergence in sub-sets of human malignancies diagnosed in multiple organs.  
 5 
 
Functional, structural, genetic, and molecular definitions of stem cell-associated 
retroviral sequences (SCARS). 
The term stem cell-associated retroviral sequences (SCARS) refers to the defined set of 
genomic regulatory sequences sustained expression of which is essential for acquisition and 
maintenance of stemness phenotype [7; 25; 26].  The canonical definition of “stemness” in 
reference to human Embryonic Stem Cells (hESC) implies a combination of the phenotypic 
features of immortality/self-renewal/asymmetrical division/pluripotency. Single cell expression 
profiling-guided deconvolution of a developmental timeline of human preimplantation embryos 
enabled the discovery of human embryonic Multi-Lineage Markers Expressing cells (MLME 
cells), emergence of which during human embryogenesis precedes lineage segregation events 
and subsequent creation of hESC [27]. Specific members of SCARS termed human 
pluripotency-associated transcripts (HPATs) have been implicated in the creation of the MLME 
cells [27]. It has been hypothesized that definition of the “stemness” phenotype for the human 
MLME cells should be expanded to include the totipotency feature and the human MLME cells 
could be defined biologically as the pan-lineage precursor cells [27].  
For cell differentiation to occur, the expression of SCARS must be silenced: hESC fails 
to properly differentiate in response to differentiation-inducing cues if SCARS expression is 
maintained and resulting cells display differentiation-defective phenotypes [28; 29]. It has been 
suggested that de-repression and sustained re-activation of SCARS expression in association 
with continuous activation of down-stream genomic regulatory targets (collectively defined as 
activation of SCARS-associated genomic regulatory networks) is the hallmark of therapy-
resistant clinically-lethal malignancies with clinical phenotypes of increased risk of therapy 
failure and high likelihood of death from cancer [7; 25; 26]. Evolutionary, SCARS are belong to 
the exceedingly large class of genomic sequences originated from transposable elements (TE) 
and comprising nearly two-third of human genome. Specifically, in hESC and human 
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preimplantation embryos SCARS represent a functionally-related and structurally-defined sub-
set of TE-derived regulatory sequences originated from LTR7/HERV-H, LTR5_Hs/HERV-K, and 
recently implicated SVA-D retrotransposons [30-32], the set of which was further narrowed by 
restrictions to human-specific (unique-to-humans)  genomic regulatory sequences [7; 25; 26; 
33-39]. 
A range of genetic and molecular definitions of SCARS directly linked to a stemness 
state extends to different classes of regulatory DNA sequences (transcription factor-binding 
sites; functional enhancer elements; alternative promoters), donors of splicing sites, and non-
coding RNA molecules. Precise mapping of individual transcriptionally-active genomic loci which 
generated RNA molecules from repetitive sequences (repeats), including highly diverse families 
of transposable elements (TE) and human endogenous retroviruses (HERV) - encoded 
sequences, became possible only recently. Advances in RNAseq technology and bioinformatics 
approaches to data retrieval, processing, and analyses, including implementation of de novo 
transcriptome assembly protocols, facilitated identification of hundreds thousands of TE-
encoded RNA molecules precisely mapped to corresponding transcriptionally active genomic 
loci in human dorsolateral prefrontal cortex [40] and across the spectrum of all major human 
cancer types [41]. Using the pan-cancer de novo transcript assembly approach, the remarkable 
complexity and ubiquitous nature of transcripts encoded by endogenous retroviral elements 
(EREs) were uncovered in human malignancies of distinct origins and diverse spectrum of 
anatomical locations [41]. It has been reported that thousands of transcripts overlapping with 
regulatory long terminal repeats (LTRs) derived from endogenous retroviruses were expressed 
in a cancer-specific manner in at least one or several related cancer types [41]. Several of these 
cancer-specific LTR-harboring transcripts represent relatively large RNA molecules exceeding 
50K nucleotides, perhaps, reflecting the read-through transcriptional activity in cancer cells due 
to the extensive chromatin reprogramming. Notably, cancer-specific RNA molecules derived 
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from individual SCARS loci representing LTR7/HERV-H and LTR5_Hs/HERV-K families 
accounted for 31% of all reported cancer-specific LTR element-overlapping transcripts that are 
expressed in more than one cancer type. These cancer-specific LTR-harboring RNA molecules 
appear to affect the expression of disease-relevant genes and to produce previously unknown 
cancer-specific antigenic peptides [41]. Therefore, it is now feasible to unequivocally map 
SCARS-harboring RNA molecules to specific transcriptionally-active genetic loci encoding these 
transcripts. 
Global DNA methylation reprogramming and SCARS activity contribute to creation of 
telomerase-positive MLME cells during human preimplantation embryogenesis. 
One of the principal molecular functions of activated SCARS is illustrated by their biological 
activities attributed to non-coding RNA (ncRNA) molecules transcribed from regulatory DNA 
segments harboring SCARS. Importantly, manifestations SCARS biological activities have been 
demonstrated for ncRNAs derived from individual genomic loci [27; 42; 43] and in human 
embryos SCARS activity has been associated with the creation of telomerase-positive cells co-
expressing genetic markers of all embryonic lineages [27]. These telomerase-positive Multi-
Lineage Markers Expressing (MLME) cells have been identified employing single cell 
expression profiling analyses of viable human blastocysts and hundreds of individual cells 
recovered from preimplantation human embryos [27; 42; 43]. Creation of cells in part resembling 
gene expression features of MLME cells was recapitulated in genetic engineering experiments, 
in which individual SCARS-encoded RNAs termed Human Pluripotency-Associated Transcripts 
(HPATs) were over-expressed in human cells [27; 42; 43]. These observations support the 
hypothesis that SCARS activation in human embryos may have contributed to the creation of 
MLME cells.  
The summary of the multi-step validation protocol of human embryonic Multi-Lineage Markers 
Expressing (MLME) cells is shown in the Table 1. The MLME phenotype was assigned to 
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individual telomerase-positive cells that co-expressed at least 6 genetic markers of the Epiblast 
(EPI) lineage; 7 genetic markers of the Trophectoderm (TE) lineage; and 4 genetic markers of 
the Primitive endoderm (PE) lineage; and cells must express all three main master pluripotency 
transcription factors (OCT4, NANOG, SOX2). First, the expression levels of 58 genetic markers 
of human embryonic lineages were considered individually in a particular single cell by 
comparing the expression values of the markers in a given cell and the median expression 
value of the marker in the population of single cells of human embryos as previously reported 
[27; 44]. The marker was considered expressed when the expression value in a cell exceeds 
the median expression value. The discovery set of 58 genetic markers of human embryonic 
lineages was utilized in these experiments and based on the above criteria a total of 135 MLME 
cells were selected from 839 telomerase-positive human embryonic cells. The discovery set of 
58 genetic markers of human embryonic lineages was reported elsewhere [27; 45; 46]. Next, 
independent sets of lineage-specific markers comprising of top 100 individual genetic markers 
for each embryonic lineage that were utilized for validation of the MLME phenotype in each 
individually-selected cell. The validation sets of lineage-specific genetic markers of human 
embryonic lineages were reported elsewhere [44]. To assess the statistical significance of the 
enrichment of the lineage-specific genetic markers in the MLME cells, p values were estimated 
using the hypergeometric distribution test. Results of these analyses revealed statistically 
significant enrichment of genes representing genetic markers of three main embryonic lineages 
among genes up-regulated in human embryonic MLME cells (Table 1). In agreement with the 
hypothesis that activities of SCARS contribute to creation of MLME cells, SCARS appear to 
affect expression of two-third of genes (8,374 of 12,735 genes; 66%) expression of which 
distinguishes MLME cells from other cells in preimplantation human embryos. Notably, SCARS 
activity affects expression of a dominant majority (84.1%) of genes up-regulated in human 
embryonic MLME cells, while expression of only a minor fraction of genes down-regulated in 
MLME cells (13.4%) appears affected by SCARS.   
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Zygote-to-embryo transition is accompanied by dramatic DNA methylation reprogramming 
which is governed by the placeholder nucleosome positioning [47]. Newly established genome-
wide dynamics of the chromatin accessibility landscape and concurrent changes of promoter 
methylation states affect expression of thousands genes and results in embryonic genome 
activation [31; 48]. Importantly, DNase I hypersensitive site (DHS) sequencing revealed that 
human transposons SVA and HERV-K harbor DHSs and are highly expressed in early human 
embryos, but not in differentiated tissues [31]. Analyses of genes comprising GES of human 
embryonic MLME cells revealed that DNA methylation reprogramming may have contributed to 
the creation and maintenance of the MLME phenotype in human preimplantation embryos 
(Figure 1). Collectively, observed in MLME cells gene expression changes of 
methyltransferases would cause marked reprogramming of genome-wide DNA methylation 
profiles by erasing the pre-existing cytosine methyl marks and establishing de novo methylation 
patterns (Figure 1A). Concurrently diminished expression of genes encoding primate-specific 
zinc finger proteins, in particular, ZNF534 and ZNF91 genes, would relieve the repressive 
chromatin from SCARS loci and facilitate activation of SCARS expression (Figure 1B). 
Consistently, during transition from the oocyte to the morula stage of human preimplantation 
embryogenesis, promoters of genes comprising the MLME GES shift from nearly exclusively 
homogenously closed (silenced) states to predominantly homogenously open (active) states 
(Figure 2). The predominantly homogenously open promoter states of genes comprising the 
MLME signature are maintained in human embryonic cells of the ICM, TE, and hESC (Figure 2).   
SCARS represent both intrinsic and integral components of human-specific genomic 
regulatory networks. 
SCARS are predominantly primate-specific regulatory sequences that is they are common for 
Modern Humans and non-human primates [7]. However, sizable fractions of different SCARS 
families are represented by human-specific (unique-to-human) regulatory sequences. For 
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example, 302 of 1222 (24.7%) full-length LTR7/HERV-H elements have been identified as 
candidate human-specific regulatory sequences, HSRS [7]. Species-specificity of SCARS is 
defined by the unique genomic coordinates of the insertions of corresponding parent 
transposons, which appear as segments of DNA present on human chromosomes and absent 
on chromosomes of non-human primates. Interestingly, 37.6% of highly active in hESC 
LTR7/HERV-H elements have been classified as HSRS [7]. This is contrast to only 19.8% 
LTR7/HERV-H that are inactive in hESC being identified as candidate HSRS (p < 0.0001). 
Therefore, globally SCARS should be viewed within the genomic regulatory context of other 
classes of HSRS [38].  
Candidate HSRS comprise a coherent compendium of nearly one hundred thousand genomic 
regulatory elements, including 59,732 HSRS which are markedly distinct in their structure, 
function, and evolutionary origin [38] as well as 35,074 human-specific neuro-regulatory single 
nucleotide changes (hsSNCs) located in differentially-accessible (DA) chromatin regions during 
human brain development [39; 49]. Unified activities of HSRS may have contributed to 
development and manifestation of thousands human-specific phenotypic traits [39]. SCARS 
encoded by human endogenous retroviruses LTR7/HERV-H and LTR5_Hs/HERV-K as one of 
the significant sources of the evolutionary origin of HSRS [7; 25-27; 33-40], including human-
specific transcription factor binding sites (TFBS) for NANOG, OCT4, and CTCF [33; 37]. It was 
interest to determine whether genes previously linked to multiple classes of HSRS, which were 
identified without considerations of genes expression of which is regulated by SCARS, overlap 
with SCARS-regulated genes. To this end, 13,824 genes associated with different classes of 
HSRS were identified using the GREAT algorithm [38; 39], subjected to the GSEA, and 
compared with the sets of SCARS-regulated genes (Figure 3) identified by shRNA interference 
[50] and CRISR/Cas-guided epigenetic silencing experiments comparing regulatory networks of 
naïve and primed hESC [30; 32]. These analyses revealed that SCARS appear to affect 
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expression of a majority (8,384 genes; 61%) of genes associated with different classes of HSRS 
(Table 2; Supplemental Table S1), in agreement with the hypothesis that a large fraction of 
SCAS-regulated genes represents an intrinsic component of human-specific genomic regulatory 
networks. Consistently, SCARS affect expression of a majority of genes (5,389 of 8,405 genes; 
64%) associated with neuro-regulatory hsSNCs [39]. Overall, the common gene set of 
regulatory targets independently defined for HSRS, SCARS, and neuro-regulatory hsSNCs 
comprises of 7,990 coding genes or 95% of all genes associated with neuro-regulatory hsSNCs 
located in DA chromatin regions during human brain development [39].  
Genes associated with HSRS and neuro-regulatory hsSNCs manifest a staggering breadth of 
significant associations with morphological structures, physiological processes, and pathological 
conditions of Modern Humans [39], indicating that a preponderance of human-specific traits 
evolved under a combinatorial regulatory control of HSRS and neuro-regulatory loci harboring 
hsSNCs. SCARS-regulated genes comprise a large fraction of these human-specific genomic 
regulatory networks and represent an integral component of genomic regulatory wiring 
governing human-specific features of early embryonic development.  
One of the important questions is whether the patterns of significant associations with 
physiological and pathological phenotypes observed for genes linked with HSRS, hsSNCs, and 
SCARS are specific and not related to the size effects of relatively large gene sets subjected to 
the GSEA [39]. To address this questions, 42,847 human genes not linked by the GREAT 
algorithm with HSRS were randomly split into 21 control gene sets of various sizes ranging from 
2,847 to 6,847 genes and subjected to the GSEA [39]. Importantly, no significant phenotypic 
associations were observed for 21 control gene sets, indicating phenotypic associations 
attributed to genes linked with HSRS, hsSNCs, and SCARS are not likely due to non-specific 
gene set size effects captured by the GSEA. These observations are highly consistent with the 
conclusion that a broad spectrum of significant phenotypic associations documented for genes 
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linked with HSRS, neuro-regulatory hsSNCs, and SCARS reflects their bona fide impacts on 
physiological and pathological phenotypes of Modern Humans. It should be underscored that 
the efficient execution of these analytical experiments was greatly facilitated by the web-based 
utilities provided by the Enrichr Bioinformatics System Biology platform [51; 52]. 
Gene set enrichment analyses (GSEA) of 8,384 genes associated with HSRS, expression of 
which is regulated by LTR7Y/B and LTR5_Hs/SVA_D enhancers and HERVH lncRNAs. 
GSEA on multiple genomics databases revealed remarkable breadth and depth of significant 
associations with physiological and pathological phenotypes of Modern Humans of 8,834 
SCARS-regulated genes linked with multiple families of HSRS (Supplemental Text S1). 
Consistent with the established role of SCARS in human embryogenesis, SCARS-regulated 
genes are significantly enriched in human embryo and neuronal epithelium according to GSEA 
of the ARCHS4 Human Tissues database. Consistently, POU5F1 and PRDM14 master stem 
cell regulators were identified by GSEA of the ESCAPE stem cell-focused database as top up-
stream regulators, while pathways in Cancer (KEGG 2019 Human database) and Axon 
Guidance (KEGG 2019 Mouse database) were scored as top significantly-enriched pathways. 
GSEA of the Allan Brain Atlas database focused on up-regulated genes identified 590 human 
brain regions among significantly enriched records, while GSEA of the Allen Brain Atlas of 
down-regulated genes identified 847 significant records (adjusted p-value < 0.05). Notably, 
seven of the top ten significantly enriched records among up-regulated genes identified the 
Dentate Gyrus, while remaining 3 of the top 10 records identified the Fields CA3 of stratum 
pyramidale and stratum lucidum of the hippocampus (Supplemental Text S1; Allan Brain Atlas 
database; up-regulated genes).  
GSEA of the Virus MINT database comprising of human genes that encode proteins known to 
physically interact with viruses and viral proteins identified the Epstein-Barr virus as the top-
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scoring record, indicating that upon entry in human cells the Epstein-Barr virus-encoded 
proteins target proteins encoded by SCARS-regulated genes. Overall, expression of nearly 60% 
of all human genes encoding virus-interacting proteins (2,574 of 4,433 VIP-encoding genes; 
58%) is regulated by SCARS.  
GSEA of 2,846 genes associated with created de novo HSRS, expression of which is regulated 
by LTR7Y/B and LTR5_Hs/SVA_D enhancers and HERVH lncRNAs. 
In human genome, there are 4,528 genes comprising putative regulatory targets of ~12,000 
created de novo HSRS [38; 39]. Notably, SCARS regulate expression of 2,846 genes (63%) of 
all genes identified as candidate regulatory targets of created de novo HSRS. GSEA of 
genomics databases revealed numerous significant enrichment records linked with 2,846 
SCARS-regulated genes, thus highlighting their potential impacts on human physiology and 
pathology (Supplemental Text S2).  
Unexpectedly, GSEA of the ENCODE and ChEA Consensus transcription factors (TFs) from 
ChIP-X database identified androgen receptor (AR) as a top-scoring candidate upstream 
regulator. In agreement with the above observations, GSEA of the ARCHS4 Human Tissues 
database identified Neuronal epithelium, Human embryo, and Prefrontal cortex as top 
significantly-enriched records (Supplemental Text S2). Pathways in Cancer (KEGG 2019 
Human database) and Axon Guidance (KEGG 2019 Mouse database) were identified as top 
significantly enriched pathways. Additionally, pathways of Integrins in angiogenesis (NCI-Nature 
2016 database) and Integrin signaling (Panther 2016 database) were identified as top-scoring 
significantly-enriched pathways (Supplemental Text S2).  
GSEA of the Jensen Tissues database identified 134 significantly enriched records indicating 
that SCARS-regulated genes associated with created de novo HSRS have been previously 
identified among genes comprising expression signatures of many human tissues. Other 
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notable findings were revealed by the GSEA of the Human Phenotype Ontology database (81 
significant records); the MGI Mammalian Phenotype 2017 database (309 significant records); 
the Allen Brain Atlas databases of up-regulated genes (284 significantly-enriched brain regions) 
and down-regulated genes (408 significantly-enriched brain regions).  
SCARS-regulated genes appear significantly enriched among genes implicated in a broad 
spectrum of human common and rare diseases. GSEA of the Rare Diseases AutoRIF ARCHS4 
Predictions database captured 353 significantly-enriched records of human rare disorders 
(Supplemental Text S2). GSEA of the Disease Perturbations from Gene Expression Omnibus 
(GEO) database of up-regulated genes identified 246 significant records, while interrogation of 
the Disease Perturbations from GEO database of down-regulated genes revealed 203 
significantly-enriched records (Supplemental Text S2). 
Lastly, according to GSEA of the Jensen Diseases database, a significant majority of SCARS-
regulated genes associated with created de novo HSGRS (2008 of 2846 genes; 71%) have 
been implicated in development and clinical manifestations of multiple types of human cancers 
(Supplemental Text S2).   
Inference of potential impacts of SCARS on development and clinical behavior of human 
malignancies.  
SCARS activation hypothesis postulates the central role of a sustained activity of SCARS in 
acquisition and maintenance of stemness features in human cancer cells, clinical manifestations 
of which are reflected in high likelihood of therapy failure and death from cancer [7; 25; 26]. This 
intrinsic propensity to evade the malignancy eradication therapies is proposed to exist even if 
SCARS-activation driven cancer is diagnosed as the early stage disease based on established 
pathomorphological and molecular criteria.  
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Observations capturing the principal molecular, genetic, and biological features attributed to 
regulatory impacts of SCARS were made in experimental models of naïve and primed hESC, 
human induced pluripotent stem cells (iPSC), and human preimplantation embryogenesis. 
These experiments identified genes expression of which is significantly altered in human cells 
subjected to targeted genetic manipulations to achieve SCARS over-expression [27; 42; 43} 
and/or silencing using shRNA interference [42; 43; 50], CRISPR/Cas gene knockout technology 
[42] as well as CRISPR/Cas-guided epigenetic silencing of SCARS [32], thus facilitating 
identification of multiple gene expression signatures (GES) reflecting fine details of 
experimentally-defined SCARS-associated genomic regulatory networks.   
Impacts of genes comprising distinct GES regulated by LTR7Y/B and LTR5_Hs/SVA_D 
enhancers and HERVH lncRNAs. 
Potential biological relevance of several experimentally-defined GES comprising distinct panels 
of SCARS-regulated genes have been evaluated using Gene Set Enrichment Analyses (GSEA) 
across multiple genomic databases as previously described [38; 39]. These analytical 
experiments were executed using the web-based tools of the Enrichr Bioinformatics System 
Biology platform [51; 52]. To date, the following GES of SCARS-regulated networks in hESC are 
available for follow-up interrogations of their biological impacts and potential translational 
significance: 
1. GES comprising a set of 1,141 genes that are regulated by both HERVH lncRNA and 
LTR5_Hs/SVA_D enhancers; 
2. GES comprising a set of 3,063 genes regulated by both LTR7Y/B enhancers and 
HERVH lncRNA; 
3. GES comprising a set of 1,477 genes regulated by both LTR7Y/B enhancers and 
HERVH lncRNA and manifesting concordant expression profiles; 
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4. GES comprising a set of 1,586 genes regulated by both LTR7Y/B enhancers and 
HERVH lncRNA and manifesting discordant expression profiles;  
The up to date summary of the key findings for each of these four SCARS GES is reported in 
the Supplemental Text S3. Notably, GSEA of 1,141 genes that are regulated by both 
LTR5_Hs/SVA_D enhancers and HERV-H lncRNA facilitated identification and characterization 
of sub-sets of SCARS-regulated genes implicated in Parkinson’s, autism, multiple types of 
cancer, and human embryonic development (Supplemental Text S3).  
GSEA of the Jensen Diseases database revealed that a significant majority of genes regulated 
by both HERV-H lncRNA and LTR7Y/B enhancers (1905 of 3063 genes; 62%) have been 
implicated in development and clinical manifestations of multiple types of human cancer. 
Similarly, a significant majority of genes regulated by both HERV-H lncRNA and LTR7Y/B 
enhancers and manifesting concordant expression profiles (972 of 1477 genes; 66%) have 
been implicated in development and clinical manifestations of multiple types of cancer 
(Supplemental Text S3). 
HSRS and SCARS regulate expression of a majority of cancer survival predictor genes 
and cancer driver genes. 
One of the approaches to evaluation of potential impacts of SCARS on development and clinical 
manifestations of human malignancies could be the assessment of regulatory effects of SCARS 
on cancer survival and cancer driver genes. To this end, analyses of 10,713 protein-coding 
genes expression changes of which are significantly associated with the increased likelihood of 
survival of cancer patients diagnosed with 17 major cancer types [53] and 460 cancer driver 
genes identified in 28 human cancer types [54] revealed that SCARS regulate a majority of 
either cancer survival genes or cancer driver genes (Tables 3; 4; Figure 4; Supplemental Text 
S4).  
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It has been observed (Table 3) that a prominent majority of human cancer survival predictor 
genes is regulated by HSRS (7,738 genes; 72%). As shown in Table 4, SCARS regulate 
expression of 7,609 of 10,713 (71%) human cancer survival predictor genes (Table 4).  
SCARS regulate expression of two-third cancer driver genes (305 of 460 genes; 66%) and as 
many as 73-75% of high-confidence cancer driver genes (Figure 4), which were defined by 
either the level of peer-reviewed literature support (Figure 1A) or the statistical significance 
levels (Figure 4B). Notably, SCARS regulate expression of a majority of cancer driver genes 
regardless of their maximum mutations’ frequency (Figure 4D). SCARS-regulated cancer driver 
genes were identified in all analyzed to date 28 types of human cancer (Table 5). From the 
therapeutic strategy stand point, it is important to map actionable cancer therapy-guiding nodes 
defined by the SCARS stemness matrix mapped to connect Cancer Driver Genes/Cancer 
Type/Regulatory SCARS (Table 5). Further details describing regulatory effects of HSRS and 
SCARS on cancer survival and cancer driver genes are reported in the Supplemental Text S4.  
Implications for mechanistic studies of normal development and pathophysiology of 
Modern Humans. 
One of the most intriguing molecular functions of SCARS is highlighted by their role as 
functionally active enhancers as well as the ability of SCARS to influence enhancers’ activity. 
Enhancer elements could be divided into functionally silent and functionally active categories. 
Exceedingly large set of functionally silent enhancers could be defined by characteristic 
chromatin marks indicating that specific DNA sequences harboring these chromatin marks may 
function as enhancer elements. Accurate molecular and genetic definitions of functionally active 
enhancers require the application of specific assays in a particular cell type as it has been 
reported for hESC [55]. It has been observed that SCARS are significantly enriched among 
regulatory DNA sequences identified in either primed or naïve hESC as functionally active 
enhancer elements [37; 55]. Furthermore, human embryonic MLME cells, creation of which was 
 18 
 
associated with SCARS activity [27], appear to capture GES of both Naïve and Primed hESC 
(Supplemental Text S5) with more significant resemblance of hESC in the Naïve state. 
Therefore, assessments of biological roles of functionally active enhancers in hESC may shed a 
light on our understanding of potential biological impacts of SCARS-associated genomic 
regulatory networks. 
Arguably, two key biologically-distinct functions of active enhancers in hESC are the 
maintenance of self-renewal and pluripotency states by restricting the differentiation potential 
and changing on demand the expression of genes linked to major embryonic lineages. Primed 
hESCs, in particular, are thought to represent a state poised to differentiation in which 
functionally active enhancers linked to differentiation of various lineages can be quickly switched 
on or off in response to developmental cues (likely in response to changes in chromatin and 
histone modification patterns). The biological role of functionally active hESC enhancers could 
be inferred by evaluating the enrichment within regulatory networks governed by naïve and 
primed hESC enhancers of genes comprising expression signatures of different human and 
non-human embryonic lineages (Table 6). In these analyses gene expression signatures of 
major embryonic lineages of distinct species, including humans, monkeys, and mice were 
evaluated [27; 45; 46; 50; 56-58]. To this end, all genes comprising expression signatures of 
distinct embryonic lineages were assessed and genes which are located in close genomic 
proximity (at a distance of 10 kb or less) to naïve and primed hESC functionally active 
enhancers were identified. It has been observed that in all instances a high proportion of marker 
genes distinguishing embryonic lineages are located in close genomic proximity to hESC 
functional enhancers (Table 6). Notably, proportions of genes associated with naïve and primed 
hESC enhancers appear similar, consistent with the hypothesis that both naive and primed 
hESC represent functionally distinct states with the complimentary relevance to mechanistic 
exploration of developmental pathways.    
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To assess the statistical significance of these findings, observed numbers of genes 
associated with hESC functional enhancers were compared to the expected values based on 
associations by chance alone. Expected values were estimated based on the number of genes 
in the human genome (63,677); number of genes associated with functional enhancers of the 
Naïve hESC (18,766); number of genes associated with functional enhancers of the Primed 
hESC (17,131); number of genes associated with functional enhancers of both Naive and 
Primed hESC (25,421); and numbers of genes in the corresponding expression signatures of 
embryonic lineages. These analyses revealed that in all instances differences between the 
observed and expected numbers of observations appear highly statistically significant (Table 6). 
These findings indicate that genomic networks governed by both naïve and primed functional 
enhancers in hESC may represent valuable models for follow-up mechanistic studies of 
regulatory mechanisms governing critical stages of the human pre-implantation embryogenesis.    
This line of investigations have been extended to evaluate the potential biological role of hESC 
functionally active enhancers by performing the proximity placement analyses of genes 
associated with regulatory networks of naïve and primed hESC functional enhancers and 
compare these with genes involved in human embryonic, neurodevelopmental, and cancer 
survival predictors' transcriptional networks (Supplemental Tables S9 and S10), which were 
previously identified in multiple independent studies {27; 30; 40; 45; 46; 50; 53; 56-60]. A 
comprehensive genome-wide proximity placement analyses identifies all genes associated with 
functional enhancers, which were defined based on the location of their genomic coordinates 
within +/- 10 Kb windows of the corresponding enhancer’s genomic coordinates [55]. All genes 
in common have been identified for a set of genes associated with enhancers and a set of 
genes comprising the expression signatures of corresponding embryonic, neurodevelopmental, 
and cancer survival predictors' networks. Finally, the assessment of statistical significance of 
observed versus expected numbers of genes in common has been performed for corresponding 
gene sets. Highly significant associations (Supplemental Tables S9 and S10) of genes defining 
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human embryonic, neurodevelopmental, and cancer survival predictors' transcriptional networks 
with naïve (Supplemental Tables S9) and primed (Supplemental Tables S10) hESC functionally 
active enhancers have been observed. Genes associated with functionally active enhancers in 
Naïve and Primed hESC are significantly enriched for genes comprising human-specific 
expression signatures of excitatory neurons (Figure 5A), radial glia (Figure 5B), induced 
pluripotent cells (Figure 5C), and human genes encoding a majority of virus-interacting proteins 
(Figure 5D). It should be noted that these regulatory genomic features of functionally active 
hESC enhancers are markedly similar to the regulatory impacts of HSRS and SCARS on genes 
implicated in pathogenesis of neurodevelopmental, neuropsychiatric, and neurodegenerative 
disorders [35; 38; 39]. The summary of observations supporting this conclusion is reported in 
the Supplemental Text S6. 
Collectively, these findings strongly argue that a comprehensive catalog of functionally active 
enhancers in hESC together with GES of SCARS-regulated genes may serve as an important 
previously unavailable resource for evidence-based mechanistic dissections of fine genomic 
regulatory architectures governing expression of genes implicated in transcriptional networks 
relevant to human development and diseases.  
Evolutionary aspects of the emergence of overlapping genetic networks associated with 
cancer and other common human disorders. 
Present analyses support the idea of shared genomic regulatory networks impacting human 
cancer survival, neuropsychiatric, neurodevelopmental, and neurodegenerative disorders. Many 
genes that expressed in the human brain tend to be long because they have more introns, 
which is also true for genes expressed in specific cells in human preimplantation embryos 
because there is a large overlapping genetic networks operating in MLME cells of human 
embryos and fetal/adult neocortex of human brains. Overall, we have more introns in our genes 
than, for example mouse, and about 10% less protein coding genes. Thus, in genomes of 
Modern Humans high transcripts’ diversity (which impacts both regulatory diversity of RNA 
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molecules and diversity of peptides and proteins) was achieved by inserting more intronic 
sequences and increasingly relying on splicing. Retrotransposition is one of the major 
mechanistic contributors to these continuing processes with major impacts on stem cells 
survival and expansion to sustain the regeneration and dying cells' replenishment in various 
tissues and organs (Figure 6). DNA sequences of long genes that are expressed and 
continuously transcribed in these long living cells for many years of the individuals' lifetime have 
a significantly higher probability to acquire and accumulate functionally deleterious, regulatory, 
and disease causing mutations. Depending on when and where it happened, it would manifest 
as different diseases: for example, in cells of coherent peripheral tissues it would be diagnosed 
as malignant tumors, while in cells of central nervous system it would be diagnosed as 
neurodevelopmental, neuropsychiatric, or neurodegenerative disorders. It has been suggested 
[33] that, in addition to deamination of methyl-cytosine, one of the main mechanisms promoting 
the increased likelihood of mutations is the RNA-mediated formation of energetically-stable 
DNA:RNA triple-stranded complexes designated R-loops, specifically, R-loops formation of 
which is driven by SCARS-encoded RNA molecules.  
Hypothesis of a singular source code for essential faithful execution of early 
embryogenesis programs and driving the emergence of disease states in human cells. 
Precisely controlled waves of activities of distinct families of transposable elements, including 
SCARS, provides a genomic source code for proper execution of high-complexity 
developmental programs during human preimplantation embryogenesis. In human embryonic 
stem cells (hESC), sustained activities of SCARS is required for maintenance of the stemness 
state. Conversely, failure to silence SCARS during neuronal differentiation of hESC is 
associated with development of differentiation-defective phenotypes, indicating that SCARS 
activity is not compatible with physiological functions of differentiated human cells. 
Consequently, aberrant activation of SCARS in long-living human cells might represent a 
genomic source code driving the emergence of various disease states, including cancer, 
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neurodegeneration, neurodevelopmental and neuropsychiatric disorders (Figure 6). In this 
contribution, experimental evidence and theoretical considerations have been summarized 
supporting the model of a singular genomic source code, activation and execution of which 
contributes to development of multiple types of human disorders. This singular genomic source 
code captures the mechanistic essence of malignant regulatory signatures. 
1. Removing of DNA and chromatin silencing marks at SCARS-encoding loci. 
2. Activation of transcription at SCARS loci and production of SCARS RNAs.  
3. Activation of a genome-wide network of functional enhancers associated with a 
pluripotent state. 
4. Genome-scale effects of functional enhancers and SCARS-encoded RNAs on DNA 
conformation dynamics and chromatin states resulting in expression changes of 
thousands genes, including known specific disease state-causing genes. 
5. Effects of SCARS-encoded RNAs on functions and maintenance of microRNAs affecting 
the stability, abundance, and translation of mRNAs. 
6. Amplification of transcriptional activation of transposable elements, including SVA, Alu, 
and LINE retrotransposons.  
7. Formation of energetically stable triple-stranded RNA/DNA complexes transitioning to 
highly prone to mutations R-loop conformations. 
8. Binding of SCARS RNAs to conformation-disordered proteins, including RNA-binding 
proteins and virus interacting proteins (VIPs). 
9. Genome-scale rewiring of and interference with liquid-liquid phase-separated 
condensates affecting chromatin regulatory states.  
10. System-scale effects on the efficiency of compartmentalization of biochemical reactions 
controlled by liquid-liquid phase-separated condensates.  
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Conclusions 
In accord with the expected in vivo regulatory role of SCARS and hESC functional enhancers 
during human embryonic development, a significant enrichment of genes comprising expression 
signatures of major embryonic lineages of distinct species, including humans, monkeys, and 
mice has been observed within regulatory networks of Naïve and Primed hESC functional 
enhancers. Results of these analyses further support the hypothesis that key regulatory features 
of human neurodevelopmental networks are engaged during the early-stages of human 
embryogenesis [33-35; Supplemental Tables S11-S12]. Analyses of regulatory networks of 
Naïve and Primed hESC functional enhancers revealed a highly consistent pattern of significant 
enrichment of genes that were previously identified as principal components of major 
neurodevelopmental networks (Supplemental Tables S9-S12), including GES of human 
neuronal and non-neuronal brain cells [59], human neurons' sub-types and neuronal diversity 
signatures [60], and human fetal brain/adult neocortex GES [35]. Consistent with the idea that 
activation of stemness genomic networks in cancer cells contributes to development of 
clinically-lethal death-from-cancer phenotypes, interrogation of regulatory networks of SCARS 
as well as Naïve and Primed hESC functional enhancers revealed a significant enrichment of 
cancer survival predictors’ genes that were defined for 17 distinct types of human malignancies 
[53]. Similar regulatory connectivity has been observed for SCARS and cancer driver’s genes 
identified for 28 human cancer types [54]. Importantly, in all instances these analyses 
demonstrated that regulatory networks of SCARS and functional enhancers operating in hESC 
in both Naïve and Primed states appear to capture distinct arrays of genomic regulatory 
networks engaged in human embryogenesis, neurodevelopmental processes, and human 
malignancies. Consequently, collective considerations of all observations summarized in this 
contribution strongly argue that highly tractable experimental model systems tailored for precise 
structure-activity-phenotype interrogations of SCARS and functional enhancers in both Naïve 
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and Primed hESC would represent a valuable, perhaps, indispensable, resource for dissections 
of principal genetic elements governing primate-specific and unique to human features of 
development, physiology, and pathology of Modern Humans.  
Perspectives 
- From the clinical perspective, perhaps, reflecting the best interest of cancer patients, the 
most important translational impact of malignant regulatory signatures would be the 
reliable early diagnosis of sub-types of malignancies with the increased risk of existing 
therapy failure and high likelihood of death from cancer. It is this yet unfulfilled promise 
of malignant regulatory signatures defining stemness of human malignancies is the main 
focus of this contribution.  
- The predominant focus of the contemporary research effort on elucidation of molecular 
interconnectivity of the stemness phenotype and development of human cancers is on 
advancement of the cancer stem cell concept. The impact of recent remarkable 
advancements of single cell genomics of preimplantation human embryos, the bone fide 
source of the stemness phenotype creation during human development, had relatively 
modest influence on cancer research and, in particular, on progress in our 
understanding of mechanistic underpinning of malignant regulatory signatures.  
- The in-depth analyses of the critically important impact of stem cell associate retroviral 
sequences (SCARS) as the essential elements of malignant regulatory signatures of 
clinically lethal human cancers will be one of the main topic of the future research. These 
studies should include precise identification and detailed structure-function analyses of 
individual transcriptionally-active regulatory genomic loci harboring SCARS and down-
stream target genes making vital contributions to pathogenesis of human malignancies 
and multiple other common disorders.  
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Methods 
Data source and analytical protocols 
A total of 94,806 candidate HSRS, including 35,074 neuro-regulatory human-specific SNCs, 
detailed descriptions of which and corresponding references of primary original contributions are 
reported elsewhere (Glinsky et al., 2015-2020; Kanton et al., 2019). Solely publicly available 
datasets and resources were used in this contribution. The significance of the differences in the 
expected and observed numbers of events was calculated using two-tailed Fisher’s exact test. 
Additional placement enrichment tests were performed for individual classes of HSRS taking 
into account the size in bp of corresponding genomic regions. Detailed description of 
methodological and analytical approaches are provided in the Supplemental Methods and 
previously reported contributions (Glinsky et al., 2015-2020).  
Statistical Analyses of the Publicly Available Datasets 
All statistical analyses of the publicly available genomic datasets, including error rate estimates, 
background and technical noise measurements and filtering, feature peak calling, feature 
selection, assignments of genomic coordinates to the corresponding builds of the reference 
human genome, and data visualization, were performed exactly as reported in the original 
publications and associated references linked to the corresponding data visualization tracks 
(http://genome.ucsc.edu/). Any modifications or new elements of statistical analyses are 
described in the corresponding sections of the Results. Statistical significance of the Pearson 
correlation coefficients was determined using GraphPad Prism version 6.00 software. Both 
nominal and Bonferroni adjusted p values were estimated. The significance of the differences in 
the numbers of events between the groups was calculated using two-sided Fisher’s exact and 
Chi-square test, and the significance of the overlap between the events was determined using 
the hypergeometric distribution test (Tavazoie et al., 1999).  
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Table 1. Enrichment of genes comprising top 100 lineage-specific genetic markers of each of three major embryonic lineages of human 
preimplantation embryos among genes that are significantly up-regulated in the MLME cells.  
Classification category Number 
of genes 
Number of up-regulated 
genes in the MLME cells 
Percent P value* Observed/expected 
ratio** 
Human genome 26178 9430 36.0   
Genetic markers of the human 
Epiblast (EPI) 
100 91 91.0 1.186E-30 2.53 
Genetic markers of the human 
Primitive Endoderm (PE) 
88 41 46.6 0.0107581 1.29 
Genetic markers of the human 
Trophectoderm (TE) 
100 81 81.0 2.799E-20 2.25 
Legend: *, p values were estimate using the hypergeometric distribution test; **, expected values were estimated based on the number of all analyzed genes 
(26178) and the number of genes significantly up-regulated in the human embryonic MLME (9430); MLME, multi-lineage markers expressing cells; A total of 819 
telomerase-positive (TERTpos) individual human embryonic cells were analyzed and each single cell was identified as the putative immortal MLME cell if it 
expressed genetic markers of each of the 3 major lineages (epiblast, EPI; throphectoderm, TE; and primitive endoderm, PE) and all three (NANOG; POU5F1; 
SOX2) pluripotent state master regulators. The MLME phenotype was assigned to individual telomerase-positive cells that co-expressed at least 6 genetic markers 
of the EPI lineage; 7 genetic markers of the TE lineage; and 4 genetic markers of the PE lineage; and three main master pluripotency transcription factors. The 
expression levels of 58 genetic markers of human embryonic lineages were considered individually in a particular single cell by comparing the expression values of 
the markers in a given cell and the median expression value of the marker in the population of single cells of human embryos as previously reported (Petropoulos 
et al., 2016; Glinsky et al., 2018). The marker was considered expressed when the expression value in a cell exceeded the median expression value. The set of 58 
genetic markers of human embryonic lineages analyzed in these experiments during the selection a total of 135 MLME cells from 839 TERTpos human embryonic 
cells is listed in the Supplemental Table S4 (Glinsky et al., 2018) and was originally reported elsewhere (Blakeley et al., 2015).. Independent sets of lineage-
specific markers comprising of top 100 individual genetic markers for each embryonic  lineage were utilized for validation of the MLME phenotype and were 
reported elsewhere (Petropoulos et al., 2016).  
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Table 2. SCARS regulate expression of a majority of 13,824 genes associated with human-specific regulatory sequences (HSRS). 
 
Legend: *, percent of all HSRS-associated genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Classification category Number of genes Percent* 
HERV-H lncRNA-regulated genes 4805 34.76 
LTR7Y/B enhancers-regulated genes 5240 37.91 
LTR5_Hs/SVA_D enhancers-regulated genes 2022 14.63 
All SCARS-regulated HSRS-associated genes 8384 60.65 
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Table 3. A prominent majority of human cancer survival predictor genes is associated with human-specific regulatory sequences (HSRS). 
   
TYPE OF CANCER 
CANCER SURVIVAL 
GENES 
HSRS-
ASSOCIATED 
 
PERCENT 
Thyroid 347 269 77.52 
Glioma 271 206 76.01 
Melanoma 205 153 74.63 
Head and neck 808 597 73.89 
Colorectal 603 440 72.97 
Renal 6070 4418 72.78 
Ovarian 504 366 72.62 
Liver 2892 2086 72.13 
Lung 662 477 72.05 
Breast 582 414 71.13 
Urothelial 1101 783 71.12 
Stomach 307 218 71.01 
Prostate 161 114 70.81 
Endometrial 1631 1153 70.69 
Cervical 717 505 70.43 
Pancreatic 1549 1075 69.40 
Testis 60 42 70.00 
All human cancer survival genes 10713 7738 72.23 
Legend: Numbers of genes in each cell reflect the sum of records in the corresponding classification category when individual genes were recorded 
as a single count. Uhlen et al. (2017) reported a total of 10,713 protein-coding genes expression changes of which are significantly associated with 
the increased likelihood of survival of cancer patients diagnosed with 17 major cancer types. Percent values were calculated as fractions of all 
cancer survival genes in the corresponding classification categories. 
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Table 4. SCARS regulate expression of a prominent majority of human cancer survival predictor genes. 
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BREAST 582 405 69.59 229 39.35 284 48.80 80 13.75 
PROSTATE 161 121 75.16 63 39.13 90 55.90 10 6.21 
PANCREATIC 1549 1112 71.79 629 40.61 772 49.84 250 16.14 
LIVER 2892 2217 76.66 1267 43.81 1565 54.11 382 13.21 
RENAL 6070 4406 72.59 2579 42.49 2881 47.46 965 15.90 
COLORECTAL 603 448 74.30 262 43.45 320 53.07 104 17.25 
CERVICAL 717 526 73.36 312 43.51 340 47.42 112 15.62 
LUNG 662 488 73.72 298 45.02 312 47.13 105 15.86 
THYROID 347 259 74.64 153 44.09 171 49.28 56 16.14 
OVARIAN 504 368 73.02 202 40.08 233 46.23 78 15.48 
ENDOMETRIAL 1631 1129 69.22 652 39.98 747 45.80 250 15.33 
UROTHELIAL 1101 772 70.12 458 41.60 483 43.87 164 14.90 
HEAD & NECK 808 558 69.06 340 42.08 369 45.67 128 15.84 
GLIOMA 271 204 75.28 115 42.44 128 47.23 48 17.71 
MEANOMA 205 148 72.20 85 41.46 107 52.20 25 12.20 
STOMACH 307 219 71.34 144 46.91 131 42.67 25 8.14 
TESTIS 60 41 68.33 23 38.33 26 43.33 11 18.33 
ALL 10713 7609 71.03 4436 41.41 5013 46.79 1641 15.32 
Legend: Numbers of genes in each cell reflect the sum of records in the corresponding classification category when individual genes were recorded 
as a single count. Uhlen et al. (2017) reported a total of 10,713 protein-coding genes expression changes of which are significantly associated with 
the increased likelihood of survival of cancer patients diagnosed with 17 major cancer types. Percent values were calculated as fractions of all 
cancer survival genes in the corresponding classification categories. 
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Table 5. SCARS-guided cancer stemness matrix of diagnostic and therapeutic targets comprising of 237 SCARS-down-regulated and 141 SCARS-activated 
cancer driver genes mapped to 28 cancer types.  
Cancer Type 
 
Number of SCARS-
silenced cancer driver 
genes 
Number of SCARS-
activated cancer 
driver genes 
Adenoid Cystic  7 4 
Bladder 30 16 
Blood 25 22 
Brain 28 16 
Breast 28 17 
Cervix 12 8 
Cholangiocarcinoma 8 4 
Colorectal 16 12 
Endometrium 30 20 
Gastroesophageal 37 26 
Head & Neck 19 6 
Kidney Clear 8 5 
Kidney Non-Clear 14 6 
Liver 18 10 
Lung AD 15 9 
Lung SC 7 3 
Lymph 36 25 
Ovarian 4 2 
Pancreas 22 17 
Pheochromocytoma 5 3 
Pleura 9 0 
Prostate 19 11 
Sarcoma 6 3 
Skin 21 13 
Testicular Germ Cell 11 8 
Thymus 7 2 
Thyroid 8 9 
Uveal Melanoma 2 1 
Number of actionable cancer therapy-guiding nodes defined by the SCARS stemness 
matrix mapped to connect Cancer Driver Genes/Cancer Type/Regulatory SCARS 
1365 
 
834 
 
Legend: AD, adenocarcinoma; SC, small cell carcinoma;  
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Table 6. Enrichment within regulatory networks of Naïve and Primed hESC active enhancers of gene expression signatures (GES) defining 
embryonic lineages of distinct species.  
Human epiblast (EPI) vs naïve hESC (hESCp#0)     
Classification category Number of genes Percent P value* Observed/Expected 
Human EPI vs hESCp#0 GES 1496 100.0   
Naïve functional enhancers network 762 50.9 1.544E-69 1.73 
Primed functional enhancers network 726 48.5 5.669E-73 1.80 
Naïve & Primed functional enhancers networks 976 65.2 4.326E-89 1.63 
Human epiblast (EPI) vs Trophectoderm (TE) GES     
Classification category Number of genes Percent P value* Observed/Expected 
Human EPI vs TE expression signature 836 100.0   
Naïve functional enhancers network 525 62.8 1.176E-89 2.13 
Primed functional enhancers network 472 56.5 2.095E-73 2.10 
Naïve & Primed functional enhancers networks 647 77.4 2.11E-109 1.94 
Monkey epiblast (EPI) GES     
Classification category Number of genes Percent P value* Observed/Expected 
Monkey EPI expression signature 719 100.0   
Naïve functional enhancers network 442 61.5 1.665E-71 2.09 
Primed functional enhancers network 399 55.5 1.687E-59 2.06 
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Naïve & Primed functional enhancers networks 529 73.6 1.003E-75 1.84 
Mouse inner cell mass (ICM) vs Trophectoderm (TE)     
Classification category Number of genes Percent P value* Observed/Expected 
Mouse ICM vs TE expression signature 497 100.0   
Naïve functional enhancers network 246 49.5 2.533E-21 1.68 
Primed functional enhancers network 211 42.5 2.314E-14 1.58 
Naïve & Primed functional enhancers networks 303 61.0 1.061E-21 1.53 
Legend: *, p values were estimated using the hypergeometric distribution test; expected values were estimated based on the number of genes in the human 
genome (63,677); number of genes associated with functional enhancers of the Naïve hESC (18,766); number of genes associated with functional enhancers of 
the Primed hESC (17,131); and number of genes associated with functional enhancers of both Naive and Primed hESC (25,421); GES, gene expression 
signature; 
 
 
 
 
 
 
 
 
 
 
 41 
 
Figure legends 
Figure 1. Expression changes of genes encoding DNA methyltransferases and primate-specific zinc finger proteins in human embryonic MLME 
cells.  
A. Telomerase-positive MLME cells manifest decreased expression of the DNMT1 gene, which is responsible for genome-wide maintenance of 
DNA methylation patterns, and increased expression of genes responsible for genome-wide de novo methylation patterns (DNMT3A, DNMT3B, 
DNMT3L).  
B. Concurrently, MLME cells exhibit decreased expression of primate-specific zinc finger proteins responsible for sequence-specific silencing of 
SCARS and other TE-harboring loci during human preimplantation embryogenesis. Collectively, these changes of gene expression cause marked 
reprogramming of DNA methylation patterns in genomes of MLME cells and are associated with activation of SCARS expression.  
MLME cells are designated as immortal multi-lineage precursor cells, iMPC [27]. 
 
Figure 2. Dynamics of promoter state’s changes of genes comprising GES of human embryonic MLME cells during human preimplantation 
embryogenesis.  
Graphs reflect the gradual transition from predominantly homogenously closed (silent) promoter state in the oocyte to predominantly homogenously 
open (active) promoter state at the morula stage. Homogenously open promoter states of genes comprising the MLME GES [27] are maintained in 
human embryonic cells of the ICM, TE, and hESC. Divergent promoter state definition refers to a transitional state of partially closed and partially 
open promoters. 
Promoter states of human genes at different stages of preimplantation embryogenesis were reported elsewhere [48]. 
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Figure 3. Genome-wide gene expression profiling experiments identify thousands of SCARS-regulated genes in hESC. 
Genome-wide RNAseq analyses were performed on genetically engineered hESC to identify genes regulated by SCARS-encoded regulatory 
signals derived from HERV-H, LTR5_Hs/SVA_D, and LTR7Y/B loci. Genes regulated by HERV-H ncRNA molecules were identified using shRNA-
mediated genetic interference [50], while genes regulated by LTR5_Hs/SVA_D and LTR7Y/B enhancers were identified employing CRISPR/Cas-
guided epigenetic silencing [32].   
 
Figure 4. SCARS regulate expression of a prominent majority of cancer driver genes.  
A total of 460 cancer driver genes reported in [54] were evaluated for regulatory dependency from SCARS.  
A. SCARS regulate expression of a prominent majority of high-confidence cancer driver genes defined by different levels of peer-review literature 
support. 
B. SCARS regulate expression of a prominent majority of high-confidence cancer driver genes defined by different levels of statistical significance. 
C. Distinct families of SCARS regulate expression of cancer driver genes collectively affecting expression of a prominent majority of cancer driver 
genes.  
D. SCARS regulate expression of a prominent majority of cancer driver genes defined by different levels of mutation frequency. 
E. Direct correlation between numbers of SCARS-activated and SCARS-silenced cancer driver genes in 28 human cancer types. 
 
Figure 5. Networks of genes regulated in Naïve and Primed hESC hESC by functionally-active enhancers are enriched for genes comprising 
human-specific expression signatures of excitatory neurons (A), radial glia (B), induced pluripotent cells (C), and human genes encoding a majority 
of virus-interacting proteins (D). 
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Figure 6. SCARS pathways – guided control of differentiated cells’ replenishment cycles. 
A. A model of the cycle in the balanced state. 
B. A model of the cycle at the loss of differentiated cells state. 
C. A model of the cycle at the completed replenishment of differentiated cells state.  
D. A model of the cycle with failed replenishment of differentiated cells due to failure of the SCARS silencing during attempts toward differentiation. 
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 46 
 
 
FIGURE 2. 
 
 
 47 
 
 
FIGURE 3. 
 
 
 48 
 
 
 
 
 
 49 
 
 
FIGURE 4. 
 
 
 50 
 
 
FIGURE 5. 
 
 
 51 
 
 
 
 
 
 52 
 
 
 
 
 
 53 
 
 
 
 
 
 54 
 
 
FIGURE 6. 
 
